New study could improve the ability to make genetic diagnoses and treat neurodevelopmental disorders.
This video explores the 4th to the 10th dimensions of time. Watch this next video about the 10 stages of AI: • The 10 Stages of Artificial Intelligence.
🎁 5 Free ChatGPT Prompts To Become a Superhuman: https://bit.ly/3Oka9FM
🤖 AI for Business Leaders (Udacity Program): https://bit.ly/3Qjxkmu.
☕ My Patreon: / futurebusinesstech.
➡️ Official Discord Server: / discord.
💡 Future Business Tech explores the future of technology and the world.
Examples of topics I cover include:
• Artificial Intelligence \& Robotics.
• Virtual and Augmented Reality.
• Brain-Computer Interfaces.
• Transhumanism.
• Genetic Engineering.
SUBSCRIBE: https://bit.ly/3geLDGO
Disclaimer:
Some links in this description are affiliate links.
As an Amazon Associate, I earn from qualifying purchases.
This video explores the 4th to the 10th dimensions of time. Other related terms: advanced civilization, ai, artificial intelligence, future business tech, future technology, future tech, future business technologies, future technologies, aliens, higher dimensions, 10th dimension, 4th dimension, 5th dimension, 6th dimension, 7th dimension, 8th dimension, 9th dimension, time travel, etc.
Retinitis pigmentosa and macular degeneration lead to photoreceptor death and loss of visual perception. Despite recent progress, restorative technologies for photoreceptor degeneration remain largely unavailable. Here, we describe a novel optogenetic visual prosthesis (FlexLED) based on a combination of a thin-film retinal display and optogenetic activation of retinal ganglion cells (RGCs). The FlexLED implant is a 30 µm thin, flexible, wireless µLED display with 8,192 pixels, each with an emission area of 66 µm2. The display is affixed to the retinal surface, and the electronics package is mounted under the conjunctiva in the form factor of a conventional glaucoma drainage implant. In a rabbit model of photoreceptor degeneration, optical stimulation of the retina using the FlexLED elicits activity in visual cortex. This technology is readily scalable to hundreds of thousands of pixels, providing a route towards an implantable optogenetic visual prosthesis capable of generating vision by stimulating RGCs at near-cellular resolution.
### Competing Interest Statement.
All authors have a financial interest in Science Corporation.
Prime editing, a mightier version of CRISPR/Cas9 technology, has been part of rigorous research and development in recent years. Now, U.S. regulators have greenlit the first-ever clinical trial for this technology.
Massachusetts-based Prime Medicine received the go-ahead from the U.S. Food and Drug Administration (FDA) after preclinical data showed that its candidate was able to correct mutations in chronic granulomatous disease (CGD).
CGD is a rare condition and affects around one in 200,000 people worldwide. It is caused by mutations in any of the six genes that code for the molecule nicotinamide adenine dinucleotide phosphate (NADPH), which is responsible for carrying electrons within cells. White blood cells called phagocytes don’t function properly, and as a result, they fail to protect the body from bacterial and fungal infections.
The ability to genetically modify haematopoietic stem cells would allow the durable treatment of a diverse range of genetic disorders but gene delivery to the bone marrow has not been achieved. Here lipid nanoparticles that target and deliver mRNA to 14 unique cells within the bone marrow are presented.
The human genome consists of around 3 billion base pairs and humans are all 99.6% identical in their genetic makeup. That small 0.4% accounts for any difference between one person and another. Specific combinations of mutations in those base pairs hold important clues about the causes of complex health issues, including heart disease and neurodegenerative diseases like schizophrenia.